Our early investigations showed the low-alloreactive KIR haplotype A to be associated with lower relapse after HSCT for leukemia (79), while in a later analysis, KIR haplotype B was associated with improved PFS and OS in patients with multiple myeloma (100). This evidence concerns the gene KIR3DL1 and plasma cell myeloma.